Acrux has returned to profitability for the first half of the 2026 financial year, reporting a significant improvement in performance as recently launched products delivered their first full revenue period.
The Australian drug delivery company recorded total revenue of $3.573 million for the six months to 31 December 2025, more than double the prior year, while net profit reached $165,000 after a substantial loss in the previous corresponding period.
>The result reflects the growing contribution of Acrux’s marketed portfolio of topical pharmaceutical products, which now includes hormone therapy spray Evamist, acne treatments Dapsone 5% and Dapsone 7.5%, and Nitroglycerin ointment. The reporting period marked the first time all four products contributed revenue for a full six months, driving a sharp increase in licensing income and strengthening the company’s financial position.
Acrux’s turnaround also follows a strategic reassessment of its pipeline as competition in the United States generic pharmaceuticals market intensified and pricing pressure reduced expected returns from some development programs. In response, the company has begun shifting its focus toward differentiated transdermal products and device-based therapies that can be brought to market more quickly. As part of this refocus, Acrux divested its Prilocaine and Lidocaine cream product in December 2025 for cash proceeds and the forgiveness of certain liabilities, allowing management to concentrate resources on higher value opportunities.
The company is also expanding into new sources of income by offering laboratory and development services to external clients. These services draw on Acrux’s long-standing expertise in formulation, testing, and regulatory support for topical medicines and generated revenue during the period, with additional projects expected to progress in the second half of the financial year. Acrux has also continued to pursue geographic expansion of its existing products, including a distribution agreement for Dapsone gel in Saudi Arabia, as it seeks to build more stable, long-term revenue streams.
Improved financial results were supported by a substantial reduction in operating expenses, driven by scaled-back research spending on discontinued projects, lower staffing costs, and the reversal of previously accrued liabilities. The combination of higher revenue and lower costs enabled the company to return to profitability and modestly strengthen its balance sheet, although management noted that ongoing performance will depend on sustaining sales growth, expanding into international markets, and maintaining access to development incentives and funding sources.